Eisai gets Japan approval for weekly LEQEMBI Pen
Eisai received Japanese approval for the LEQEMBI Pen, a once-weekly 500 mg subcutaneous autoinjector for early Alzheimer’s, adding an at-home option alongside IV dosing. Eisai leads development with Biogen; studies cited say the safety profile is similar to IV.
Eisai said it received Japanese approval for the LEQEMBI Pen, a once-weekly 500 mg subcutaneous autoinjector for early Alzheimer’s, giving patients an at-home option alongside IV dosing. Eisai leads development with Biogen, and cited studies showed a safety profile similar to IV.